Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
07/2003
07/03/2003WO2003053967A1 Aroyl pyridinones
07/03/2003WO2003053966A2 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
07/03/2003WO2003053946A1 7-amino-benzothiazole derivatives as adenosine receptor ligands
07/03/2003WO2003053925A1 Pyrrolidine-2-ones as factor xa inhibitors
07/03/2003WO2003053923A2 Pyrrolidine derivatives as prostaglandin modulators
07/03/2003WO2003053471A1 Aqueous sustained-release formulations of proteins
07/03/2003WO2003053449A1 Use of 7-monohydroxyethylrutoside for the treatment of haematological disorders, particurlarly beta-thalassemia
07/03/2003WO2003053424A1 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production
07/03/2003WO2003053401A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
07/03/2003WO2003053364A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
07/03/2003WO2003053219A2 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/03/2003WO2002070657A3 93870, a human g-protein coupled receptor and uses therefor
07/03/2003WO2002036761A3 Compositions and methods for the diagnosis of cancer
07/03/2003WO2002024754A8 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
07/03/2003WO2002020049A3 Eiav chimeric vaccine and diagnostic
07/03/2003US20030125559 Methods for synthesizing ether compounds and intermediates therefor
07/03/2003US20030125519 Ligand for the c-kit receptor and methods of use thereof
07/03/2003US20030125371 Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
07/03/2003US20030125368 (1,2,4) triazol-1-yl)-benzenesulfonyl derivatives useful to treat osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals; cyclooxygenase (COX)-2 inhibitor
07/03/2003US20030125361 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis
07/03/2003US20030125354 Aromatic compounds containing urea or thiourea groups are useful for terating cytokine mediated diseases
07/03/2003US20030125344 Rho-kinase inhibitors
07/03/2003US20030125343 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
07/03/2003US20030125342 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
07/03/2003US20030125324 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents
07/03/2003US20030125259 Administering to the mammal a therapeutically acceptable amount of a octa or nonapeptide compound to inhibit the angiogenesis
07/03/2003US20030125250 Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
07/03/2003US20030125247 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein
07/03/2003US20030125238 Hemoglobin-based oxygen carriers are prepared by reacting hemoglobin with oxidatively ring-opened polysaccharides such as hydroxyethyl starch or dextran, and storing the resultant conjugate under conditions which allow it to transform to a
07/03/2003US20030125232 Stabilized proteins with engineered disulfide bonds
07/03/2003US20030124677 Amino-terminally truncated MCP-2 as chemokine antagonists
07/03/2003US20030124626 Method of screening antiplatelet
07/03/2003US20030124596 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
07/03/2003US20030124115 A carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin; highly enhanced in vivo half-life due to increased carbohydrate content; no antigenicity
07/03/2003US20030124056 Carrier molecules
07/03/2003CA2510745A1 Human antibodies against human glycoprotein vi and their use
07/03/2003CA2471461A1 Pyrrolidine-2-ones as factor xa inhibitors
07/03/2003CA2471373A1 Modified tridegins, their preparation and their use as transglutaminase inhibitors
07/03/2003CA2471096A1 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
07/03/2003CA2471085A1 Aroyl pyridinones
07/03/2003CA2470594A1 Leptin proteins
07/03/2003CA2470576A1 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/03/2003CA2469884A1 7-amino-benzothiazole derivatives as adenosine receptor ligands
07/03/2003CA2469372A1 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production
07/03/2003CA2468083A1 Use of heterocyclic carboxamides to treat anemia
07/03/2003CA2465890A1 Aqueous sustained-release formulations of proteins
07/02/2003EP1323826A1 A cell line expressing mutated human tissue - type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein
07/02/2003EP1323737A2 Il-3 variant hematopoiesis fusion protein
07/02/2003EP1323711A1 Novel phenylalanine derivatives
07/02/2003EP1323432A1 Complexes of cyclodextrins with potassium ion homeostasis regulators
07/02/2003EP1322769A2 Protein phosphatases
07/02/2003EP1322760A2 G-protein coupled receptors
07/02/2003EP1322755A1 Human and mouse targeting peptides identified by phage display
07/02/2003EP1322752A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
07/02/2003EP1322673A1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
07/02/2003EP1322645A2 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof
07/02/2003EP1322643A1 Piperazin-2-one amides as inhibitors of factor xa
07/02/2003EP1322637A2 Quaternary amidino based inhibitors of factor xa
07/02/2003EP1322631A2 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai
07/02/2003EP1322618A1 Amino heterocyclic compounds (factor x a? inhibitors 14)
07/02/2003EP1322610A2 PIPERAZINE BASED INHIBITORS OF FACTOR Xa
07/02/2003EP1322378A1 Method and device for avoiding alteration of a substance having biological activities
07/02/2003EP1322350A1 E-ptfe foil impregnated with an encapsulated bioactive substance
07/02/2003EP1322322A2 Compounds and methods for inhibiting alpha-1 beta-1 integrins
07/02/2003EP1322310A1 Alpha v integrin receptor antagonists
07/02/2003EP1322309A2 High affinity small molecule c5a receptor modulators
07/02/2003EP1224180B1 Substituted azoles
07/02/2003EP1200837A4 A method for predicting the presence of haemostatic dysfunction in a patient sample
07/02/2003EP0954292B1 Pharmaceutical formulations with delayed drug release
07/02/2003EP0758248B1 Formulations for factor ix
07/02/2003CN1427837A Ortho-substituted anthranilic acid amides and their use as medicaments
07/02/2003CN1427818A Factor VIIA inhibitor (thio) urea derivatives, their preparation and their use
07/02/2003CN1427725A Casein derived peptides and uses thereof in therapy
07/02/2003CN1427717A Hydrophilic/lipophilic polymeric matrix dosage for mulation
07/02/2003CN1427716A Carbohydrate medical solution and sulphite stabilisator in multiple compartment container and use thereof
07/02/2003CN1427011A Hemopoiesis factor and its application
07/02/2003CN1426795A Composition for increasing leukocyte and its application
07/02/2003CN1112930C P1, P4-dithio-P2,P3-monochloromethylene 5'5-diadenosine P4,P4-tetraphosphate as antithrombotic agent
07/01/2003US6586573 Comprising a bulking agent, stabilizing agents, sodium chloride and a buffering agent; decreased risk of transmitting a virus; used in treating hemophilia
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586467 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus
07/01/2003US6586459 Antithrombotic agents
07/01/2003US6586398 Chemically modified novel erythropoietin stimulating protein compositions and methods
07/01/2003US6585997 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
07/01/2003US6585995 Administering to a subject to inhibit a vaso-occlusive event an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level
06/2003
06/26/2003WO2003052106A1 Method of screening compounds
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003052051A2 Adeno-associated virus (aav) serotype 8 sequences
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051851A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051372A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003WO2003051362A2 Polymorphs of clopidogrel hydrogensulfate
1 ... 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 ... 671